Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes

NCT00261417 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00261417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00261417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Dose-Response and Safety of Tesaglitazar Therapy in Japanese Subjects With Type 2 Diabetes
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2004
Completion date
October 31, 2005
Enrollment
250
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes